A rapid, accurate, POC disposable influenza and sars-COV-2 molecular diagnostic

Ended Definitive Contract Awarded Last action

Contract number
75A50121C00019
Awardee
Awarding agency
Obligated
$41,169,014

Award facts

Contract value 79% obligated
  • $41,169,014.00 Current, with exercised options
  • $52,239,640.00 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 1 offer Negotiated Proposal / Quote
Pricing
Cost Sharing
Place of performance
San Jose, CA 95134, USA
Legislative mandates

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Supplemental Agreement for work within scope P00019 $0
Supplemental Agreement for work within scope P00018 $0
Supplemental Agreement for work within scope P00017 $0
Supplemental Agreement for work within scope P00016 $0
Supplemental Agreement for work within scope P00015 $0
Supplemental Agreement for work within scope P00014 $2,065,992
Supplemental Agreement for work within scope P00013 $0
Other Administrative Action P00012 $0
Supplemental Agreement for work within scope P00011 $0
Other Administrative Action P00010 $0
Supplemental Agreement for work within scope P00009 $0
Other Administrative Action P00008 $1,291,668
Supplemental Agreement for work within scope P00007 $0
Other Administrative Action P00006 $0
Other Administrative Action P00005 $0
Other Administrative Action P00004 $0
Supplemental Agreement for work within scope P00003 $0
Exercise an Option P00002 $25,479,183
Other Administrative Action P00001 $0
Original award $12,332,171
Show all 20

About this award

Visby Medical, Inc. was awarded a $52.2 million definitive contract by the Office of the Assistant Secretary for Preparedness and Response (ASPR) on February 1, 2021, to develop a rapid, accurate point-of-care disposable molecular diagnostic test for influenza and SARS-CoV-2. The contract, which operates under a cost-sharing pricing model, is scheduled for completion by May 31, 2026, with performance taking place in San Jose, California. This award aligns with ASPR's Biomedical Advanced Research and Development Authority (BARDA) mission to advance medical countermeasures against biological threats through research and development of diagnostics and other medical solutions.

The contract represents a significant investment in point-of-care diagnostic capabilities, building on Visby Medical's existing expertise in rapid PCR testing platforms. The company's established experience delivering COVID-19 diagnostics through concurrent federal contracts, including awards from the National Institutes of Health and the Department of the Army, demonstrates its capability to execute this program. No set-aside designation applies to this contract. The deliverable supports pandemic preparedness objectives by providing clinicians with an instrument-free, rapid diagnostic solution capable of detecting two major respiratory pathogens in under 30 minutes.

Quick answers

Who was awarded contract 75A50121C00019?

75A50121C00019 was awarded to Visby Medical, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on February 1, 2021.

How much is contract 75A50121C00019 worth?

The government has obligated $41,169,014 on 75A50121C00019. Its potential value, with all options, is $52,239,640.

Was contract 75A50121C00019 competed?

The extent of competition for 75A50121C00019 was full and open competition. The government received 1 offer.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award